ArticleJournal of clinical microbiology2016
Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Clinical Outcomes in Adult Patients Receiving Definitive Cefazolin Therapy for Community-Acquired Enterobacterales Bacteremias across Minimum Inhibitory Concentration Breakpoints.The Canadian journal of hospital pharmacy · 2026Article
- Retrospective Evaluation of the Incidence, Clinical Characteristics and Outcomes of Gram-Negative Bacterial Infections in Patients with Hematologic Malignancies.Pathogens (Basel, Switzerland) · 2025Article
- Genomic surveillance for multidrug-resistant or hypervirulent Klebsiella pneumoniae among United States bloodstream isolates.BMC infectious diseases · 2022Article
- Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.Frontiers in pharmacology · 2022Review
- Effect on Antimicrobial Resistance of a Policy Restricting Over-the-Counter Antimicrobial Sales in a Large Metropolitan Area, São Paulo, Brazil.Emerging infectious diseases · 2022Article
- Genomic diversity of antimicrobial resistance in non-typhoidalMicrobial genomics · 2021Article
- Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.Antimicrobial agents and chemotherapy · 2021Article
- Reporting antimicrobial susceptibilities and resistance phenotypes in Staphylococcus spp.: a nationwide proficiency study.The Journal of antimicrobial chemotherapy · 2021Article
- Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected withInfection and drug resistance · 2021Article
- Amino AcidBiology · 2020Article
- Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.Antimicrobial agents and chemotherapy · 2020Article
- Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics Tests.Open forum infectious diseases · 2020Article
- We Cannot Do It Alone: The Intersection of Public Health, Public Policy, and Clinical Microbiology.Clinics in laboratory medicine · 2019Review
- VetCAST Method for Determination of the Pharmacokinetic-Pharmacodynamic Cut-Off Values of a Long-Acting Formulation of Florfenicol to Support Clinical Breakpoints for Florfenicol Antimicrobial Susceptibility Testing in Cattle.Frontiers in microbiology · 2019Article
- Pneumonia in hospitalized neurologic patients: trends in pathogen distribution and antibiotic susceptibility.Antimicrobial resistance and infection control · 2019Article
- Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.Infectious diseases and therapy · 2017Review
- En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.Frontiers in microbiology · 2017Review
- Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the Ship.Clinical microbiology reviews · 2017Review
- Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Current infectious disease reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2010, the Clinical and Laboratory Standards Institute (CLSI) lowered the MIC breakpoints for many beta-lactam antibiotics to enhance detection of known resistance amongEnterobacteriaceae The decision to implement these new breakpoints, including the changes announced in both 2010 and 2014, can have a significant impact on both microbiology laboratories and antimicrobial stewardship programs. In this commentary, we discuss the changes and how implementation of these updated CLSI breakpoints requires partnership between antimicrobial stewardship programs and the microbiology laboratory, including data on the impact that the changes had on antibiotic usage at our own institution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.